Review of Pharmacology - 9E (2015)

New Drugs
100. Ecallantide: A plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema in patients
years of age and older.
101. Eculizumab: It is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby
inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 It
has now been approved for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic
microangiopathy. It is already being used for paroxysmal nocturnal hemoglobinuria.
102. Efalizumab: Monoclonal antibody against CD 11 for psoriasis.
103. Elosulfase alfa: It is a purified human enzyme ‘N-acetylgalactosamine-6-sulfatase’ produced by recombinant DNA
technology in a Chinese hamster ovary cell line. It is indicated for Mucopolysaccharidosis type IVA (MPS IVA; Morquio
A syndrome).
104. Eltrombopag: A thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with
chronic immune (idiopathic) thrombocytopenic purpura.
105. Enfuvirtide: Fusion inhibitor useful for the treatment of HIV infection.
106. Entecavir: New viral DNA polymerase inhibitor for HBV.
107. Enzalutamide: An androgen receptor inhibitor like flutamide. It is specifically indicated for the oral treatment of patients
with metastatic castration-resistant prostate cancer who have previously received docetaxel. It is an androgen receptor
inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to
competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and
interaction with DNA.
108. Epoprostenol and Treprostinil: PGI2 analogues useful for the treatment of pulmonary hypertension.
109. Eribulin mesylate: A microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer.
110. Eslicarbazepine acetate: It is a voltage-gated sodium channel blocker indicated as adjunctive treatment for partial-onset
seizures.
111. Estramustine: Combination of estrogen and mechlorethamine used for the treatment of prostatic carcinoma.
112. Etravirine: Non-nucleoside reverse transcriptase inhibitor (NNRTI) which in combination with other antiretroviral agents
is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatmentexperienced
adult patients.
113. Everolimus: It is a mTOR inhibitor approved for treatment of patients with subependymal giant cell astrocytoma
(SEGA) and renal angiomyolipoma associated with tuberous sclerosis (TS), a rare genetic disorder. This approval
was for treatments of SEGA that cannot be treated with surgery. It is also approved for the treatment of progressive
neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.
Everolimus is supplied as a tablet for oral administration.
114. Exenatide: Recombinant GLP analog useful in diabetes mellitus.
115. Ezogabine: It enhances transmembrane potassium currents mediated by the KCNQ family of ion channels. By this
mechanism, it is thought to stabilize the resting membrane potential and reduce brain excitability. It is specifically
indicated as adjunctive treatment of partial-onset seizures in adults.
116. Febuxostat: It is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with
gout.
117. Fedotozine: New k opioid receptor antagonist for diarrhea dominant IBS.
118. Felbamate: NMDA blocker useful in epilepsy It can cause aplastic anemia.
119. Ferric carboxymaltose: It is an iron carbohydrate complex used as an intravenous injection for iron replacement. It is
indicated for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory
response to oral iron or adults who have non-dialysis dependent chronic kidney disease.
120. Fesoterodine: A competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with
symptoms of urge urinary incontinence, urgency, and frequency.
121. Fidaxomicin: It is a narrow-spectrum macrocyclic antibiotic and is bactericidal against C difficile in vitro It acts by
inhibiting RNA synthesis by RNA polymerases It is specifically indicated in adults for oral treatment of Clostridium
difficile-associated diarrhea. It can cause gastrointestinal hemorrhage, anemia and neutropenia.
122. Filgrastim and Lenograstim: Recombinant G-CSF used for cancer chemotherapy induced leukopenia.
123. Fingolimod: A sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms
of multiple sclerosis.
124. Fomivirsen: Antisense oligonucleotide useful against CMV retinitis.
125. Fospropofol disodium: An intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult
patients undergoing diagnostic or therapeutic procedures.
126. Frovatriptan, Rizatriptan, Zolmitriptan, Eletriptan and Almotriptan: 5HT1B/1D agonists useful for the treatment of
acute migraine attacks (similiar to sumatriptan).
725
General New Pharmacology
Drugs
https://kat.cr/user/Blink99/